The Epstein-Barr virus (EBV) is one of the world’s most common viruses, thought to be lurking in 95 percent of adults. For most, it causes no obvious symptoms.
But EBV is more than a short-term infection.
Once it enters the body, EBV can stay for life, and it has been linked to several cancers, multiple sclerosis, and other severe health complications. Now, new research has given us a promising way to fight it.
A team from the Fred Hutchinson Cancer Center and the University of Washington in the US developed antibodies that target two proteins on the surface of EBV particles.
We don’t just report the news, we deliver it through the voices of multiple expert staff writers, each selected to broaden our scope and deepen our storytelling.
